Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery

Core Insights - Predictive Oncology Inc. has introduced a unique 3D cell culture model aimed at enhancing cancer drug discovery and future drug development [1][4] - The 3D cell culture market is projected to grow from $1.4 billion in 2022 to nearly $5.3 billion by 2032, reflecting a compound annual growth rate (CAGR) of over 14% [1][5] Company Overview - Predictive Oncology is leveraging AI and machine learning to expedite early drug discovery, with a scientifically validated AI platform, PEDAL, that predicts tumor response to drug compounds with 92% accuracy [6] - The company maintains a biobank of over 150,000 assay-capable heterogeneous human tumor samples, providing extensive AI-based drug discovery solutions [6] Industry Context - Organ-specific 3D cell cultures offer a more accurate representation of human tissue architecture compared to traditional 2D assays, improving predictions of clinical outcomes and optimizing candidate selection for clinical development [2][4] - The application of 3D cell cultures spans various fields, including pharmaceuticals, regenerative medicine, cancer research, and toxicology, significantly enhancing the accuracy of drug efficacy, toxicity, and pharmacokinetics predictions [5]